摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(1H-pyrazol-1-yl)acetophenone | 25699-97-2

中文名称
——
中文别名
——
英文名称
3-(1H-pyrazol-1-yl)acetophenone
英文别名
1-(3-pyrazol-1-yl-phenyl)-ethanone;1-m-Acetylphenyl-pyrazol;1-[3-(1H-Pyrazol-1-yl)phenyl]ethan-1-one;1-(3-pyrazol-1-ylphenyl)ethanone
3-(1H-pyrazol-1-yl)acetophenone化学式
CAS
25699-97-2
化学式
C11H10N2O
mdl
——
分子量
186.213
InChiKey
WRDDECAIOZVXSW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    64-65 °C
  • 沸点:
    331.4±25.0 °C(Predicted)
  • 密度:
    1.13±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    34.9
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Copper-Catalyzed Arylation of Nitrogen Heterocycles from Anilines under Ligand-Free Conditions
    作者:Dounia Toummini、Anis Tlili、Julien Bergès、Fouad Ouazzani、Marc Taillefer
    DOI:10.1002/chem.201404982
    日期:2014.11.3
    The arylation of pyrazole and derivatives can be achieved by coupling arenediazonium species (formed in situ from anilines) by using a catalytic system that employs low‐toxicity and inexpensive copper metal under very mild and ligand‐free conditions (T=20 °C). From other nitrogen heterocycles, the presence of an additive (NBu4I) significantly improves the efficiency of the catalytic system. These results
    吡唑和衍生物的芳基化反应可以通过使用催化系统偶联槟榔重氮物种(由苯胺原位形成)来实现,该催化系统在非常温和且无配体的条件下(T = 20°C)使用低毒性和廉价的铜金属。与其他氮杂环相比,添加剂(NBu 4 I)的存在可显着提高催化体系的效率。这些结果代表C的第一实施例从芳基重氮物种N键的形成。
  • Ruthenium- and Rhodium-Catalyzed Direct Carbonylation of the Ortho C−H Bond in the Benzene Ring of <i>N</i>-Arylpyrazoles
    作者:Taku Asaumi、Takuya Matsuo、Takahide Fukuyama、Yutaka Ie、Fumitoshi Kakiuchi、Naoto Chatani
    DOI:10.1021/jo049864j
    日期:2004.6.1
    The direct carbonylation of C−H bonds in the benzene ring of N-phenylpyrazoles via catalysis by ruthenium or rhodium complexes is described. The reaction of N-phenylpyrazoles with carbon monoxide and ethylene in the presence of Ru3(CO)12 or Rh4(CO)12 resulted in the site-selective carbonylation of the ortho C−H bonds in the benzene ring to give the corresponding ethyl ketones. A variety of functional
    描述了通过钌或铑络合物催化的N-苯基吡唑苯环中CH键的直接羰基化。在Ru 3(CO)12或Rh 4(CO)12存在下,N-苯基吡唑与一氧化碳和乙烯的反应导致苯环中邻位C-H键的位点选择性羰基化,得到相应的乙基酮。苯环上的各种官能团都是可以容忍的。基于p K a,N-苯基吡唑具有比预期更高的反应性吡唑共轭酸的分子量值。用于该反应的溶剂的选择是重要的,并且N,N-二甲基乙酰胺(DMA)给出了最好的结果。
  • Ligand-Directed Construction of Zn(II) Complexes from Zero-Dimensional Metallomacrocycle to One-, Two-, and Three-Dimensional Coordination Polymers Based on N-Donor and β-Diketone Bifunctional Ligands
    作者:Ping Yang、Jin-Ji Wu、Hai-Yun Zhou、Bao-Hui Ye
    DOI:10.1021/cg200850r
    日期:2012.1.4
    synthesized by the reaction of the bifunctional ligands and Zn(II) salts under similar experimental conditions. Structural analyses show that the ligands act as a tridentate and bind to two Zn(II) ions as a two-connected linker, generating a variety of geometries from discrete binuclear [2 + 2] metallomacrocycles (3 and 6) to a one-dimensional looped-chain coordination polymer (4) and two-dimensional
    六个新的配合物[Zn 2(L 1)4 ]·2H 2 O·DMF(1),[Zn 2(L 2)4 ] 3 ·13H 2 O(2),[Zn 1.5(L 3)3 ] 2(3),Zn(L 4)2 ·2H 2 O(4),Zn(L 5)2 ·2CHCl 3(5)和[Zn(L 6)2 ] 2(6)(其中HL 1 = 1-(4-(1H-咪唑-1-基)苯基)丁烷-1,3-二酮,HL 2 = 1-(4-(1H-苯并咪唑-1-基)苯基)丁烷-1,3-二酮,HL 3 = 1-(4-(1H-吡唑-1-基)苯基)丁烷-1,3-二酮,HL 4 = 1-(3-(1H-咪唑-1- yl)苯基)丁烷-1,3-二酮,HL 5 = 1-(3-(1H-苯并咪唑-1-基)苯基)丁烷-1,3-二酮,HL 6 = 1-(3-(1H-吡唑-1-基)苯基)丁烷-1,3-二酮是通过双官能配体与Zn(II)盐在相似的实验条件下反应合成的。结构分析
  • SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
    申请人:Millennium Pharmaceuticals, Inc.
    公开号:US20140329836A1
    公开(公告)日:2014-11-06
    This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    本发明提供了式(I)的化合物:其中R1、R2、G、n、p和q的值如规范所述,可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或障碍的方法。
  • INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US20160145251A1
    公开(公告)日:2016-05-26
    Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    本文披露了抑制由肌动蛋白相关转录因子和血清反应因子或肌动蛋白相关转录因子和血清反应因子(“MRTF / SRF”)介导的基因转录的抑制剂,以及它们在治疗或预防癌症和纤维化方面的使用方法。特别地,本文披露了公式(I)和公式(II)的化合物及其药学上可接受的盐:其中取代基如所述。
查看更多